Selective Forms of Therapy in the Treatment of Inflammatory Bowel Diseases

Kofla-Dłubacz, Anna; Akutko, Katarzyna; Krzesiek, Elżbieta; Jamer, Tatiana; Braksator, Joanna; Grębska, Paula; Pytrus, Tomasz; Stawarski, Andrzej

doi:10.3390/jcm11040994

Cited by 7 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other drugs effectively used in the treatment of IBD, which have the ability to target the immune system response modulation, include Janus Kinases Inhibitors and antibodies that inhibit the migration of leukocytes to the gastrointestinal tract, such as vedolizumab (anti-α4 β7 integrins), abrilumab (anti-α4β7 IgG2), etrolizumab (anti-β7) or sphingosine-1 Phosphate Receptor Modulators. The development of new forms of therapy was possible thanks to the recognition of the interdependencies regulating the final immune response, and further research seems to be promising in the context of individualizing treatment and reducing the general effect of previously used drugs [ 63 , 64 , 65 , 66 ]. The scheme of IBD pathogenesis and the mechanisms of action of biological drugs in IBD patients are presented in Figure 1 and Figure 2 .…”

Section: Discussionmentioning

confidence: 99%

Etiology of IBD—Is It Still a Mystery?

Kofla-Dłubacz

Pytrus

Akutko

et al. 2022

IJMS

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBD), including colitis ulcerosa and Crohn’s disease, are chronic diseases of the gastrointestinal tract for which the cause has not been fully understood. However, it is known that the etiology is multifactorial. The multidirectional network of interactions of environmental, microbiological and genetic factors in predisposed persons lead to an excessive and insufficiently inhibited reaction of the immune system, leading to the development of chronic inflammation of the gastrointestinal walls, the consequence of which is the loss of the function that the intestine performs, inter alia, through the process of fibrosis. Detailed knowledge of the pathways leading to chronic inflammation makes it possible to pharmacologically modulate disorders and effectively treatthese diseases. In this review, we described the primary and adaptive immune system response in the gut and the known immune pathogenetic pathways leading to the development of IBD. We also described the process leading to intestinal tissue fibrosis, which is an irreversible consequence of untreated IBD.

show abstract

Section: Discussionmentioning

confidence: 99%

Etiology of IBD—Is It Still a Mystery?

Kofla-Dłubacz

Pytrus

Akutko

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…El ustekinumab es un anticuerpo monoclonal humanizado IgG1 Kappa dirigido contra la subunidad P40 común para las IL 12 y 23 10 . Se aprobó por primera vez en 2019 como tratamiento para la CU moderada a grave tras el estudio UNIFI, que demostró su eficacia y seguridad 9,[12][13][14][15] . Y posteriormente el estudio UNIFI LTE demostró la persistencia de la eficacia a largo plazo, así como su adecuado perfil de seguridad en el seguimiento hasta 156 semanas y la baja Figura 6.…”

Section: Discussionunclassified

Novedades en colitis ulcerosa: a propósito de la aprobación en México de un nuevo mecanismo de acción anti-interleucinas 12 y 23 (ustekinumab)

Martínez-Silva¹

2022

IMIDS

View full text Add to dashboard Cite

La colitis ulcerosa representa una de las dos principales entidades de la enfermedad inflamatoria intestinal; de causa desconocida, condicionada por un mecanismo etiopatogénico mediado por el sistema inmunitario innato y adaptativo, donde intervienen citocinas proinflamatorias conocidas como interleucinas (IL); el mecanismo mediado por el grupo de las IL-12 e IL-23 tiene un efecto proinflamatorio y estimulan el proceso de diferenciación de las células T mediante CD4+ en respuestas Th1 y Th17. El ustekinumab es un fármaco que suprime el efecto funcional de la actividad de la IL-12 e IL-23, que ha demostrado ser eficaz para inhibir la respuesta inflamatoria excesiva en la mucosa gastrointestinal. Reportado en los resultados en los estudios UNIFI, que demuestran la respuesta clínica, remisión clínica, remisión libre de esteroides, mejoría histológica y un buen perfil de seguridad en el manejo de los pacientes con colitis ulcerosa de moderada a grave refractaria a terapia convencional y/o con uso previo de anti-factor de necrosis tumoral alfa.

show abstract

“…The results from this study showed that CRP levels were significantly reduced from baseline (2.35 mg/dL vs 5.00 mg/dL, P = 0.002), 56% (18/32) of patients treated with dual biologic therapy maintained clinical remission after 3 mo, and that 11 of 32 patients were still in endoscopic remission after 8 mo[ 37 ]. Currently, growing numbers of newer biologics and SMDs are included in the candidate pools for DTTs, including anti-IL-23 agents such as mirikizumab, risankizumab, brazikumab and guselkumab, anti-integrin agents such as etrolizumab and ontamalimab[ 38 ], new SMDs such as PDE-4 inhibitors, as well as IL-6 inhibitors and S1PR agonists[ 4 , 39 , 40 ].…”

Section: The Current Status Of Biological Combinations In Ibdmentioning

confidence: 99%

Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease

Xu¹,

Zhu²,

Guo³

2022

World J Gastroenterol

View full text Add to dashboard Cite

Treatment strategies for inflammatory bowel disease (IBD) are rapidly evolving with the development of biologics and small molecule drugs (SMDs). However, these drugs are not guaranteed to be effective in all patients, and a “ceiling effect” of biologic monotherapy may occur. This issue highlights an unmet need for optimizing the use of biologics and predicting therapeutic responses. Thus, the development of new drugs with novel mechanisms of action is urgently needed for patients with primary nonresponse and secondary loss of response to conventional biologics and SMDs. In addition, combining different biologics or SMDs has been proposed as a novel strategy to enhance treatment efficacy in IBD, which theoretically has multidimensional anti-inflammatory potential. Based on the current evidence available for IBD, dual targeted therapy may be a promising strategy for refractory IBD patients who have failed in multiple biologic trea-tments or who have extraintestinal manifestation. Additionally, identifying the subgroup of IBD patients who are responding to biological combination therapies is also equally important in stable disease remission. In this review, we sum-marize the newly developed biologics and SMDs and the current status of bio-logics/SMDs to highlight the development of individualized treatment in IBD.

show abstract

Selective Forms of Therapy in the Treatment of Inflammatory Bowel Diseases

Cited by 7 publications

References 36 publications

Etiology of IBD—Is It Still a Mystery?

Etiology of IBD—Is It Still a Mystery?

Novedades en colitis ulcerosa: a propósito de la aprobación en México de un nuevo mecanismo de acción anti-interleucinas 12 y 23 (ustekinumab)

Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease

Contact Info

Product

Resources

About